Weekly Digest – February 2025 Weekly Digest – February 2025 10 Feb 2025: Pfizer and Astellas’ PADCEV (Enfortumab vedotin) plus KEYTRUDA (pembrolizumab) shows long-term efficacy in first-line treatment of locally advanced or metastatic urothelial cancer (la/mUC) The EV-302 trial (KEYNOTE-A39) […]
Contact:
info@ciscientists.com
+1-908-212-7484
Optimal Dose
For a subscription, please provide your email id